ETFIQData as of Nov 19, 2026. · etfiq.com/funds/arkg

ARKG Fact Sheet: ARK Genomic Revolution ETF

Share
$38.00
close, Nov 20, 2026

Over the year to Nov 19, 2026, ARKG returned +47.7% in total and charged 0.75% a year.

1-year total return
+39.7%
VOO +7.2% to Nov 20, 2026
Expense ratio
0.75%
a year
Net assets
$1.7bn
on Nov 19, 2026
Net flow, 12 months to Jul 31, 2026
−$1.7m
monthly N-PORT basis to Jul 31, 2026

Growth of $10,000, 1 year

ARKG $14,773 +47.7% · VOO $11,147 +11.5% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WindowTotal return
1 month−23.8%
3 months−23.2%
Year to date+31.2%
1 year+39.7%
3 years+40.0%
5 years−44.2%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
TEMPUS AI INC-CL A9.01%
TWIST BIOSCIENCE CORP8.57%
10X GENOMICS INC-CLASS A7.79%
CRISPR THERAPEUTICS AG5.33%
GUARDANT HEALTH INC5.19%
ABSCI CORP4.86%
ELI LILLY & CO4.63%
ILLUMINA INC4.61%
NATERA INC4.50%
SCHRODINGER INC3.50%

ARKG top ten by weight, 58.0% of the fund, of its 35 equity positions, from the holdings published by its issuer for Nov 19, 2026.

Facts

Holds 35 stocks in genomics and gene editing, 5% of its weight in S&P 500 companies · First traded Oct 31, 2014 · Benchmark S&P 500 Index, measured by VOO, which tracks the same index

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, ARKG Fact Sheet: ARK Genomic Revolution ETF. Data as of Nov 19, 2026. https://etfiq.com/funds/arkg/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/arkg.